ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The brokerage currently has a $2.50 price target on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 25.00% from the stock’s current price.
According to Zacks, “ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada. “
Separately, HC Wainwright reissued a “buy” rating on shares of ESSA Pharma in a research note on Friday, May 17th.
ESSA Pharma Company Profile
ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.